| (Taipei, Taiwan. 19
December 2005) – CDIB BioScience Venture Management (CBVM),
a life-science venture management company with operations in
the United States and Taiwan. Under the leadership of CBVM
and assistance from BPIPO (Biotechnology & Pharmaceutical
Industries Program Office, MOEA), CBVM has acquired MDS
Fermentation Technologies from MDS Pharma Services. MDS
Fermentation Technologies is the contract fermentation
business previously known as Panlabs. It is now called
Panlabs Biologics.
Founded in 2002, CBVM is the
largest dedicated life science venture fund in Taiwan, with
a total capital of NT 2.5 billion (USD 76 million). The fund
targets global life sciences / healthcare investments and
seeks to create value for both investors and its portfolio
companies. With the rapid global development in biotech
industry, CBVM intends to create opportunities for joint
ventures and corporate partnership arrangement on a
worldwide basis. CBVM is capitalized primarily by
commitments from the government development fund, major
insurance companies, major financial institutions,
electronic giants, and other institutional investors in
Taiwan. For more information, visit CBVM’s Web site at
www.cdibbioscienc.com.
Panlabs Biologics began
offering contract fermentation services for strain
improvement and process development in 1970. The facility
was founded and is still located in Taiwan. Panlabs offers
expertise in classical strain improvement and fermentation
process development, production strain technology and
microbial extracts. For more information, visit Panlab’s Web
site at www.panlabsbiologics.com.
MDS Pharma Services (MDSPS)
is a leading provider of innovative drug discovery and
development solutions. The company has numerous facilities
located around the world and provides expertise to each
stage of the drug discovery and development process. For
more information, visit MDSPS’ Web site at www.mdsps.com.
|